CASE REPORT {#s1}
===========

A 67-year-old man with esophageal cancer underwent esophagectomy, which was complicated by kidney injury necessitating continuous renal replacement therapy (CRRT), respiratory failure, and ventilator-associated pneumonia due to carbapenem-resistant *Klebsiella pneumoniae* (\[CR-Kp\] isolate 4-A). Ventilator-associated pneumonia was treated with ceftazidime-avibactam (1.25 grams intravenous every 8 hours \[q8hrs\]) and inhaled gentamicin (80 milligrams q12hrs) for 15 days. Ten days after treatment, he developed leukocytosis. Computerized tomography scan revealed an intra-abdominal abscess. Ceftazidime-avibactam was restarted empirically. Drainage culture grew meropenem-susceptible *K pneumoniae*, reported as extended-spectrum β-lactamase (ESBL)-producing (isolate 4-B) \[[@CIT0001]\]. Ceftazidime-avibactam was continued for 15 days, the abscess was surgically drained, and the patient improved. Several weeks later, the patient developed meropenem-susceptible, ESBL-producing *K pneumoniae* bacteremia (isolate 4-C). He was treated successfully with meropenem 1 gram intravenous q12hrs (adjusted for creatinine clearance \~40 mL/min) for 18 days and subsequently discharged.

CHARACTERIZATION OF ISOLATES {#s2}
============================

Isolate 4-A was resistant to all β-lactams except ceftazidime-avibactam ([Table 1](#T1){ref-type="table"}). Isolates 4-B and 4-C were ceftazidime-avibactam-resistant, but meropenem-susceptible ([Figure 1](#F1){ref-type="fig"}); ceftriaxone, cefepime, and aztreonam MICs were reduced ≥16-fold from baseline. Isolates underwent whole-genome sequencing, as described previously \[[@CIT0002]\]. Isolate 4-A was multilocus sequence type (ST)-258, *K pneumoniae* carbapenemase-3 (KPC-3)-producing. Isolates 4-B and 4-C were ST258, with glutamic acid for alanine and tyrosine for aspartic acid substitutions at KPC-3 Ambler positions 177 (A177E) and 179 (D179Y), respectively. Isolates clustered within a novel phylogenetic sublineage of clade II ST258, which also includes isolates from 3 other patients at our center in whom ceftazidime-avibactam resistance emerged \[[@CIT0002]\].

###### 

Meropenem Time-Kill Results Against *Klebsiella pneumoniae* That Developed Ceftazidime-Avibactam Resistance^a^

  Isolate   ST        KPC Variant    MIC (µg/mL)^b^   Log-Kill at 24 Hours in Presence of Meropenem^c^                                   
  --------- --------- -------------- ---------------- -------------------------------------------------- ----------- --------- --------- -----------
  **1-A**   **258**   **KPC-3**      **2 (S**)        **512**                                            **128**     ^**d**^   ^**d**^   **+3.53**
  1-B       258       D179Y, T243M   256              \>512                                              0.5 (S)     −4.97     −4.27     −4.97
  1-C       258       D179Y, T243M   256              \>512                                              0.25 (S)    −5.94     −4.94     −5.96
  **2-A**   **258**   **KPC-3**      **4 (S**)        **256**                                            **32**      ^**d**^   ^**d**^   **+3.57**
  2-B       258       V240G          32               \>512                                              8           −6.14     −6.14     −6.14
  2-C       258       D179Y          \>256            \>512                                              4           −4.64     −5.64     −4.64
  **3-A**   **258**   **KPC-3**      **2 (S**)        **256**                                            **32**      ^**d**^   ^**d**^   **+3.52**
  3-B       258       D179Y          128              512                                                0.25 (S)    −5.98     −5.98     −5.98
  3-C       258       D179Y          64               512                                                0.125 (S)   −3.18     −3.18     −5.83
  **4-A**   **258**   **KPC-3**      **1 (S**)        **256**                                            **16**      ^**d**^   ^**d**^   **+3.52**
  4-B       258       A177E, D179Y   256              256                                                0.25 (S)    −3.70     −5.16     −6.16
  4-C       258       A177E, D179Y   128              256                                                0.25 (S)    −3.26     −2.54     −5.96

Abbreviations: cfu, colony-forming units; CLSI, Clinical Laboratory Standards Institute; KPC, Klebsiella pneumoniae carbapenemase; MIC, minimum inhibitory concentration; S, susceptible based on CLSI interpretive criteria; ST, sequence type. Bolded rows represent the baseline isolate from each of the 4 patients.

^a^Time-kill assays were performed in duplicate for each isolate, using a 1 × 10^6^ cfu/mL inoculum in cation-adjusted Mueller-Hinton broth. Bactericidal responses were defined as a ≥3-log decrease in cfu/mL from the starting inoculum at 24 hours.

^b^MICs were determined by broth microdilution according to reference methods (1). CLSI interpretative criteria were applied to define susceptibility as follows: ceftazidime-avibactam, ≤8 µg/mL; ceftazidime, ≤4 µg/mL; meropenem, ≤1 µg/mL.

^c^Difference in concentration (log~10~) compared with baseline (time 0). Data are shown for a representative replicate of each isolate.

^d^Not tested.

![Time-kill responses of ceftazidime-avibactam-resistant *Klebsiella pneumonia* to meropenem. NOTE: Time-kill results in the presence of meropenem. Circle = control (no drug), triangle = 4× minimum inhibitory concentration (MIC), cross = 8× MIC, square = 16 μg/mL.](ofx10101){#F1}

Time-kill assays were performed on longitudinal isolates from our 4 patients, using meropenem at 16 µg/mL (achievable serum concentration) \[[@CIT0003]\], 4× minimum inhibitory concentration (MIC), and 8× MIC ([Table 1](#T1){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}). Meropenem (16 µg/mL) did not inhibit CR-Kp with wild-type *bla*~KPC-3~, but it was bactericidal at 24 hours against *bla*~KPC-3~ mutants (4× MIC, 8× MIC, and 16 µg/mL log-kills: −3.18 to −5.98, −2.54 to −6.14, and −4.64 to −6.16 log~10~, respectively).

![Restoration of meropenem susceptibility among ceftazidime-avibactam-resistant *Klebsiella pneumonia*. Etest results for meropenem and ceftazidime-avibactam against baseline isolate 4-A (left) and follow-up isolate 4-C (right).](ofx10102){#F2}

DISCUSSION {#s3}
==========

Ceftazidime-avibactam, a novel β-lactam/β-lactamase inhibitor, is US Food and Drug Administration-approved for treating complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI). The agent is active against carbapenem-resistant *Enterobacteriaceae* (CRE) expressing KPCs, but not metallo-β-lactamases. Ceftazidime-avibactam is likely to be widely used against off-label CRE infections. We used ceftazidime-avibactam to treat 37 CRE-infected patients (29 without cIAI or cUTI) \[[@CIT0004]\]. Thirty-day clinical success and mortality rates were 59% (22 of 37) and 76% (28 of 37), respectively. In a multicenter series, 36 CRE-infected patients (20 without cIAI or cUTI) received compassionate-use ceftazidime-avibactam \[[@CIT0005]\]. Clinical cure and in-hospital survival rates were 69% (25 of 36) and 61% (22 of 36), respectively. Results did not differ in either study if ceftazidime-avibactam was combined with another antibiotic. Outcomes were comparable to those reported previously for CRE-infected patients treated with ≥2 in vitro active agents \[[@CIT0006]\]. Acute kidney injury was described in only 3 patients between studies, suggesting lower toxicity than with colistin or aminoglycosides.

Ceftazidime-avibactam resistance has emerged in \~10% of CR-Kp-infected patients treated at our center \[[@CIT0002], [@CIT0004]\]. Thus far, these are the only cases reported to develop during treatment. Resistance has been diagnosed after 10--19 days of drug exposure, exclusively in KPC-3-producing ST258 isolates. It is conferred by plasmid-borne *bla*~KPC-3~ mutations, which reduce MICs of carbapenems (often restoring susceptibility) and other β-lactams \[[@CIT0002], [@CIT0007]\]. The D179Y variant, alone or in combination with other mutations, predominates in patients and after in vitro passage \[[@CIT0008], [@CIT0009]\], and manifests the strongest phenotypes \[[@CIT0002], [@CIT0007]\]. Most mutations have arisen within the KPC Ω-loop (positions 165--179), thereby enhancing ceftazidime affinity and possibly restricting avibactam binding \[[@CIT0009]\]. The A177E mutation is newly reported. As in our case, *K pneumoniae* with mutant *bla*~KPC-3~ may be identified as ESBL-producers (rather than KPC-producers) if carbapenemase screening is triggered by elevated carbapenem MICs. Failure to detect *bla*~KPC~ in a timely fashion may facilitate nosocomial dissemination.

Meropenem at clinically achievable concentrations was bactericidal against ceftazidime-avibactam-resistant *K pneumoniae* in vitro, and it eradicated isolate 4-C from our patient's bloodstream. However, meropenem resistance has emerged in ceftazidime-avibactam-resistant isolates from our patients during in vitro passage at subinhibitory meropenem concentrations \[[@CIT0010]\]. In most passage experiments, resistance to ceftazidime-avibactam and other β-lactams was retained. Therefore, until more data are available, the role of carbapenems in treating patients is unclear. Combination regimens merit investigation. Of note, ceftazidime-avibactam dosing is not established for CRRT; our patient received half the conventional dose. Better pharmacokinetic data are needed in CRRT and other specialized populations and for various types of invasive infections.

CONCLUSIONS {#s4}
===========

In conclusion, clinicians should be alert for the inevitable emergence of more widespread ceftazidime-avibactam resistance. To best use and preserve ceftazidime-avibactam, resistant isolates should be studied for resistance mechanisms and genome and plasmid content.
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